Category Archives: ALS Treatment

19 Dec 2020 The anti-inflammatory medication masitinib met its primary endpoint in an Alzheimers disease trial, according to topline data announced December 16 by its sponsor, the Paris-based company AB Science. In the six-month Phase 2b/3 study of 718 AD patients, the drug appeared to halt cognitive decline, with the treatment group, on average, notching slight improvements on the ADAS-Cog. Continue reading →

Newly Launched JT's Angel Fund delivers emergency financial assistance to mid-Atlantic ALS families during pandemic. Managing this charitable fund is a deeply personal mission for everyone involved, including Josh's family, the Virginia Gentlemen Foundation, and the ALS Association's Virginia Chapter. Josh's father, Virginia Beach developer Bruce Thompson, along with non-profit group the Virginia Gentlemen Foundation, has raised over $30 million to fulfill Josh's vision of providing research funding for ALS and to build facilities for people with disabilities Continue reading →

The Herald News WARWICK, RI A Wish Come True is making its 17th annual Polar Plunge at Easton Beach in Newport a virtual event this year due to the COVID-19 pandemic. Instead of plunging into the ocean, A Wish Come True is asking plungers to dump a bucket of ice water on themselves and share a video of it on social media platforms like Facebook and Instagram with the hashtag #AWCTPolarPlunge. The event was inspired by the Ice Bucket Challenge made popular by former Boston College baseball player Peter Frates, who lost his battle with ALS in 2019 Continue reading →

When the coronavirus pandemic hit the in March, Lafayette-based VieMed Healthcare became a go-to source for much-needed ventilators. Hospitals, physicians and as many as 16 state governments reached out for ventilators when the surge first hit and ventilators were scarce. Company founders Casey Hoyt and Mike Moore helped clinicians and hospitals learn how to assemble and use the ventilators and made about 30 videos in 48 hours that taught clinicians how to use a home ventilator during peak surge periods when people were scrambling to help patients breathe. Continue reading →

Overview Amyotrophic lateral sclerosis (a-my-o-TROE-fik LAT-ur-ul skluh-ROE-sis), or ALS, is a progressive nervous system disease that affects nerve cells in the brain and spinal cord, causing loss of muscle control. ALS is often called Lou Gehrig's disease, after the baseball player who was diagnosed with it. Continue reading →

Above: Listen to anaudio version of this story. Everybody who knows Jimmy Judge knows that the only place you could find him on a Friday night in the fall is on the sidelines cheering for his 17-year-old son Jakie. Continue reading →

Ness Ziona-based biotech firm Kadimastem has shown encouraging results of Cohort B of its Phase 1/2a clinical trial for AstroRx, its Amyotrophic Lateral Sclerosis (ALS) treatment trial. The objective of this trial was to evaluate the safety of their treatment, with a secondary objective of the trial of estimating its preliminary efficacy. The treatment was developed by Kadimastem and contains functional, healthy astrocytes (nervous system support cells) derived from Human Embryonic Stem Cells (hESC) that aim to protect diseased motor neurons Continue reading →

NEW YORK, Dec. Continue reading →

The ALS Treatment Market research report helps the market players to execute phenomenal business techniques and therefore, it has featured driving contenders vital moves including acquisitions, business extension, mergers, joint efforts, adventures, limited time exercises, branding, and product dispatches. The SWOT analysis incorporates inner and outside variables, just as present and future capability of the market. Continue reading →

December 16, 2020 11:55 ET | Source: AB Science multilang-release AB SCIENCE WILL HOST A LIVE WEBCAST ON THURSDAY DECEMBER 17, 2020 ON MASITINIB RESULTS IN ALZHEIMERS DISEASE Paris, December 16, 2020, 6pm CET AB Science SA (NYSE Euronext FR0010557264 AB) will host a live webcast on December 17, 2020 with key opinion leaders to discuss recently reported results from the Phase 2B/3 masitinib trial in Alzheimers Disease. Continue reading →